SGLT2 inhibitors have recently been investigated as a potential anti-cancer therapy and have been shown to induce apoptosis or inhibit proliferation of breast cancer [41, 42], renal cell carcinoma [43], and hepatocellular carcinoma [44] cells at high concentrations in vitro. This evidence concerns the gene SLC5A2 and renal cell carcinoma.